Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review

[1]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[2]  Rajasekar Thirugnanam,et al.  Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  K. Messer,et al.  Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  E. Estey,et al.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.

[5]  H. Dombret,et al.  Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. , 2008, Blood.

[6]  M. Pasquini,et al.  Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  F. Lo‐Coco,et al.  Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation , 2007, Bone Marrow Transplantation.

[8]  M. Tallman.  Treatment of relapsed or refractory acute promyelocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[9]  S. Asano,et al.  Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony‐stimulating factor‐combined high‐dose cytarabine, fludarabine, and total body irradiation , 2006, European journal of haematology.

[10]  A. Stamatoullas,et al.  Arsenic Trioxide (AS2O3) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All-Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy. , 2005 .

[11]  P. Vespa,et al.  Analysis of Thrombi Retrieved from Cerebral Arteries of Patients with Acute Ischemic Stroke. , 2005 .

[12]  R. Ohno,et al.  Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies , 2005, International Journal of Hematology.

[13]  T. Papayannopoulou.  Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. , 2004, Blood.

[14]  L. Escoda,et al.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. , 2003, Blood.

[15]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[16]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[17]  J. Esteve,et al.  A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute Promyelocytic Leukemia , 1999 .

[18]  F. Mandelli,et al.  Therapy of molecular relapse in acute promyelocytic leukemia. , 1999, Blood.

[19]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[20]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[21]  K. Akashi,et al.  Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia , 1997, Bone Marrow Transplantation.

[22]  M. Labopin,et al.  Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1997, Blood.

[23]  K. Akashi,et al.  Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group. , 1997, International journal of hematology.

[24]  Margaret Gross-King.  For Acute Myelogenous Leukemia and Myelodysplastic Syndrome: This list of clinical research protocols relating to acute myelogenous leukemia and myelodysplastic syndrome is compiled for your convenience. , 1997 .

[25]  M. Vignetti,et al.  Autologous Bone Marrow Transplantation for Acute Promyelocytic Leukemia in Second Remission: Prognostic Relevance of Pretransplant Minimal Residual Disease Assessment by Reverse-Transcription Polymerase Chain Reaction of the PML/RARα Fusion Gene , 1997 .

[26]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[27]  J. Román,et al.  Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia , 1997, Bone Marrow Transplantation.

[28]  A. Grañena,et al.  European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). , 1994, Bone marrow transplantation.

[29]  K. Akashi,et al.  Evaluation of leukaemic contamination in peripheral blood stem cell harvests by reverse transcriptase polymerase chain reaction , 1993, British journal of haematology.

[30]  R. Arceci.  Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience , 2009 .

[31]  Yoo-Jin Kim,et al.  The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. , 2006, Haematologica.

[32]  R. Ribeiro,et al.  Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. , 2006, Hematology. American Society of Hematology. Education Program.

[33]  J. Bourhis,et al.  Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Ferrara,et al.  Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. , 2004, Haematologica.

[35]  G. Martinelli,et al.  Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission. , 1998, Haematologica.

[36]  T. Barbui,et al.  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.

[37]  M. Vignetti,et al.  Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. , 1997, Blood.

[38]  K. Ikebuchi,et al.  Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. , 1994, Bone marrow transplantation.

[39]  K. Akashi,et al.  Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia. , 1994, Bone marrow transplantation.